ALBERTO CALVO-GARCIA

Dr. ALBERTO CALVO-GARCIA

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ACALBERTO CALVO-GARCIA
ALBERTO CALVO-GARCIA
EHEsther RAMÍREZ HERRÁIZ
Esther RAMÍREZ HERRÁIZ
ICIrene María Llorente Cubas
Irene María Llorente Cubas
BDBlanca Varas De Dios
Blanca Varas De Dios
JGJuana Benedí González
Juana Benedí González
RGRosario García-Vicuña
Rosario García-Vicuña
Background/Aim: Baricitinib (BAR) is the first oral selective Janus kinase inhibitor approved in Europe for rheumatoid arthritis (RA). Real-world data are still needed to clarify its long-term benefits/risk profile. This study aimed to evaluate the effectiveness, persistence, adherence, and safety of BAR in a real-world setting. Methods: An ambispective study was conducted between October 2017 and December 2021 in RA patients starting BAR. The effectiveness was evaluated, assessing changes from the baseline of the Disease Activity Score using 28-joint counts-C reactive protein (DAS28CRP), and the achievement of low disease activity/remission. Drug persistence was evaluated using Kaplan–Meier analysis. Adherence was estimated using the medication possession ratio (MPR) and the 5-item Compliance Questionnaire for Rheumatology. Safety was assessed determining global incidence proportion and adverse event adjusted incidence rates. Results: In total, 61/64 recruited patients were finally analyzed, 83.6% were female, 78.7% were seropositive, the mean age was 58.1 (15.4) years, and the disease duration was 13.9 (8.3) years. A total of 32.8% of patients were naïve to biologics and 16.4% received BAR as monotherapy. The median exposure to BAR was 12.4 (6.6–31.2) months (range 3.1–51.4). A significant change in DAS28CRP was observed after treatment (difference −1.2, p = 0.000). 70.5% and 60.7% of patients achieved low disease activity or remission, respectively, and 50.8% (31/61) remained on BAR throughout the follow-up, with a median persistence of 31.2 (9.3–53.1) months. The average MPR was 0.96 (0.08) and all patients exhibited “good adherence” according to the questionnaire. In total, 21.3% of patients discontinued baricitinib due to toxicity. Conclusions: In our real-world practice, BAR demonstrated effectiveness, large persistence, high adherence to treatment, and an acceptable safety profile.

28 March 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
ACALBERTO CALVO-GARCIA
ALBERTO CALVO-GARCIA
EHEsther RAMÍREZ HERRÁIZ
Esther RAMÍREZ HERRÁIZ
ICIrene Maria Llorente Cubas
Irene Maria Llorente Cubas
BDBlanca Varas De Dios
Blanca Varas De Dios
ABAlberto Morell Baladrón
Alberto Morell Baladrón
RGRosario García-Vicuña
Rosario García-Vicuña
Background/Aim: Baricitinib (BAR) is the first oral selective Janus kinase inhibitor approved in Europe for rheumatoid arthritis (RA). Real-world data are still needed to clarify its long-term benefit/risk profile. This study aimed to evaluate the effectiveness, persistence, adherence, and safety of BAR in a real-world setting. Methods: An ambispective study was conducted between October 2017 and December 2021 in RA patients starting BAR. Effectiveness was evaluated by change from baseline in the Disease Activity Score using 28-joint counts-C reactive protein (DAS28CRP), and achievement of low disease activity/remission. Drug persistence was evaluated by Kaplan-Meier analysis. Adherence was estimated by medication possession ratio (MPR) and the 5-item Compliance Questionnaire for Rheumatology. Safety was assessed by global incidence proportion and adjusted incidence rates of adverse events. Results: 61/64 recruited patients were finally analyzed, 83.6% female, 78.7% seropositive, mean age of 58.1 (15.4) years, and disease duration of 13.9 (8.3) years. 32.8% were naïve to biologics and 16.4% received BAR on monotherapy. After a median exposure to BAR of 12.4 (6.6-31.2) months (range 3.1-51.4), a significant change in DAS28CRP was observed (difference -1.2, p=0.000). A total of 70.5% and 60.7% patients achieved low disease activity or remission, respectively and 50.8% (31/61) patients remained on BAR during follow-up with a median persistence of 31.2 (9.3-53.1) months. The average MPR was 0.96 (0.08) and all patients were “good adherents” by questionnaire. 21.3% patients discontinued baricitinib due to toxicity. Conclusion: In our real-world practice, BAR demonstrated effectiveness, large persistence, high adherence to treatment and acceptable safety profile.

11 March 2019
Verified
Conference Paper
Open access
PDF file
SGS Ruiz Garcia
S Ruiz Garcia
EPE Alañón Plaza
E Alañón Plaza
ACALBERTO CALVO-GARCIA
ALBERTO CALVO-GARCIA
IMI Cidoncha Muñoz
I Cidoncha Muñoz
MLM Ruiz López
M Ruiz López
ABA Morell Baladrón
A Morell Baladrón
Background Direct oral anticoagulants (DOACs) require different follow-up than vitamin K inhibitors. DOACs dose adjustment depends on indication, age, renal function and weight, which could made dosage errors easier. Purpose To analyse the use of DOACs and their prescription profile in the indications funded by the national health system. Material and methods The retrospective observational study considered patients admitted in February 2017 with a prescription of some DOACs included in the Hospital Pharmacotherapeutic Guide (apixaban, dabigatran and rivaroxaban). Data sources: electronic medical records, primary care prescription and hospital electronic prescription. Data collected: age, sex, DOAC, previous anticoagulant and reason for change, dose, schedule, indication and creatinine level at admission and discharge. Results Thirty-five patients were included, of whom 51.4% were female; median age was 82 (IQR 78.75–86.25) years. Sixteen (47.1%) patients had previously received acenocoumarol, owing to overdose or haemorrhage (five patients), stroke (four), poor control of INR (four) and patient preference (three). Thirty-six DOACs were prescribed: dabigatran in four (11.1%) patients, rivaroxaban in eight (22.2%) and apixaban in 24 (66.7%). Two (5.7%) patients were treated with rivaroxaban to prevent thromboembolism in knee replacement with 10 mg every 24 hours for 34 and 49 days, respectively (2 weeks is the optimal duration). In 33 (94.3%) patients, the indication was prevention of stroke and embolism in patients with non-valvular atrial fibrillation with some risk factor. Twenty-four patients were admitted with DOACs: four with dabigatran, one of them (25%) underdosed; six with rivaroxaban, two of them (33.3%) underdosed; 14 patients with apixaban, five (35.7%) underdosed; and three (21.4%) impossible to evaluate because the weight was unknown. During the admission 10 treatments were initiated, four suspended and three patients died. Three patients were discharged with dabigatran, one of them (33.3%) underdosed; three with rivaroxaban, two of them (66.7%) underdosed; and 23 with apixaban, nine of them (39.1%) underdosed; and three with weight undocumented. Conclusion DOACs require less follow-up than classic anticoagulants, however it is necessary that the dose adjustment is optimised, the control of treatment length and the promotion of the use of these drugs for their approval indications to ensure their safety and efficacy. References and/or acknowledgements No conflict of interest.

1 June 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
CVCristina Valero
Cristina Valero
ACALBERTO CALVO-GARCIA
ALBERTO CALVO-GARCIA
NCN. García Castañeda
N. García Castañeda
AOAlberto Ortiz
Alberto Ortiz
ILI. Llorente
I. Llorente
ERE. Ramirez
E. Ramirez
Background: The Janus Kinase (JAKi) inhibitors Baricitinib (BAR) and Tofacitinib (TOF) are indicated for moderate to severe active rheumatoid arthritis (RA). Data about safety, effectiveness in refractory patients and adherence in real clinical practice in our population are scarce. Objectives: An evaluation of safety, adherence and reasons to consider suspension of JAKi in routine clinical practice. Methods: Retrospective observational study of patients with RA treated with BAR and TOF according to usual clinical practice between September 2017 - December 2019. Data were collected from the electronic medical record and from the Dominion® Outpatient Drug Dispensing program. Demographic, clinical, laboratory and treatment-related variables were collected, including reasons for discontinuing JAKi (inefficiency and toxicity). Adherence was calculated using the Compliance Questionnaire on Rheumatology (CQR-5), and the average possession ratio (RMP), which is defined as the number of days with treatment dispensed between the total days of the period analyzed, considering the adherent patient when RMP had a ≥ 0.8. Laboratory abnormalities were defined according to normal limit values (NLV) and specifications of data sheet. A descriptive analysis was performed using proportions, medians and interquartile ranges (IQR) using the SPSS v.15 program. Results: Thirty patients were included in treatment with BAR and nine with TOF. The median age was 62.9 (RIQ 49.9-74.4), 34 (87.2%) were women, 28 (71.2%) anti-CCP and 32 (82.1%) were rheumatoid factor positive, with erosive disease in 34 (87,2%) patients. In the previous treatment, 9 (23.1%) were naive to biological, 6 (15.4%) had received 1 biological, 18 (46.1%) 2 biologicals, and 6 (15.4%) ≥ 3 biologicals. The median treatment time was 8.4 months (RIQ 6.5-20.3) in BAR and 13.2 (RIQ 3.9-20.7) in TOF. The reasons for consider suspension shown in Table 1. Treatment Discontinuation Safety results of the treatment shows the safety results. Conclusion: In our population, mostly refractory to biological, more than half of the patients maintain treatment with JAKi, with optimal adherence. The main reason for the suspension of both drugs was inefficiency. The most frequent adverse effects were hypercholesterolemia in both groups and infections in BAR, with a high frequency of herpes zoster. No cardiovascular or thromboembolic events were observed. Disclosure of Interests: Cristina Valero: None declared, Alberto Calvo Garcia: None declared, Noelia García Castañeda: None declared, Ana Ortiz: None declared, Irene Llorente Speakers bureau: Gebro, Janssen, Sanofi, Lilly., Blanca Varas: None declared, Santos Castañeda: None declared, Rosario Garcia de Vicuna Grant/research support from: BMS, Lilly, MSD, Novartis, Roche, Consultant of: Abbvie, Biogen, BMS, Celltrion, Gebro, Lilly, Mylan, Pfizer, Sandoz, Sanofi, Paid instructor for: Lilly, Speakers bureau: BMS, Lilly, Pfizer, Sandoz, Sanofi, Esther Ramirez: None declared

14 December 2022 in ONCOLOGY
Verified
Journal Article
Open access
PDF file
ACALBERTO CALVO-GARCIA
ALBERTO CALVO-GARCIA
MAMaría Abánades
María Abánades
SGSilvia Ruíz- García
Silvia Ruíz- García
ARAna Román
Ana Román
JFJavier Fernández
Javier Fernández
RBRamón Bosch
Ramón Bosch
Alberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.

11 March 2019
Verified
Conference Paper
Open access
PDF file
SGS Ruiz Garcia
S Ruiz Garcia
EHE Ramírez Herraiz
E Ramírez Herraiz
ACALBERTO CALVO-GARCIA
ALBERTO CALVO-GARCIA
CNC Martínez Nieto
C Martínez Nieto
ABA Morell Baladrón
A Morell Baladrón
Background Etanercept is a tumour necrosis factor (TNF) inhibitor indicated for active rheumatoid arthritis (RA) as monotherapy or in combination with methotrexate. Biosimilar drugs currently commercialised are Benepali and Erelzi. Purpose To evaluate biosimilar etanercept effectiveness in patients with RA and calculate the saving due to use them versus the original drug. Material and methods Retrospective observational study in a cohort of patients with RA treated with a biosimilar etanercept from January 2017 to August 2018. Data collected: drug, age, sex, dose, schedule, concomitant disease-modifying antirheumatic drugs (DMARD), previous biological drugs, treatment length, baseline and final disease activity score (DAS28). Data sources: electronic medical records and outpatients’ electronic prescription. Costs considered were hospital average prices. Results Thirty-two patients were included; but only 16 had DAS28 documented. 81.3% were female, median age 61 (IQR 50.75–66.75) years and median treatment duration 186 (IQR 107.25–263.75) days. All patients were treated with a concomitant DMARD. Baseline and final DAS28 means differences were statistically significant (p=0.002). 56.3% of patients were naive, whose DAS28 difference was statistically significant (p=0.006). Twenty-five per cent of patients received etanercept as a third line of treatment, with a DAS28 difference statistically not significant (p=0.496). Eight (50%) patients received Benepali, 75% were female, median age 61 (IQR 54.00–66.25) years and median treatment duration 253.50 (IQR 212.50–418.50) days. Baseline and final DAS28 means differences were statistically significant (p=0.014). Eight (50%) patients received Erelzi. 87.5% female, median age of 60.50 (IQR 46.00–69.00) years and median treatment duration of 143.50 (IQR 92.50–180.00) days. DAS28 difference was statistically not significant (p=0.068). The use of biosimilar in these patients would suppose a saving of 27.47% versus the original drug (34.93% Benepali, 20% Erelzi). Conclusion Effectiveness results were similar to the original drug. Both biosimilar drugs show a decrease in DAS28, although Erelzi was statistically not significant possibly because of its lower treatment length in this study. DAS28 difference was statistically significant in naive patients, however, in those who received more than two lines, there was not a decrease in this value. The use of biosimilar drugs instead of original drugs entails an important saving. These results require confirmation in long-term treatments. References and/or acknowledgements Matsuno H, et al. Ann Rheum Dis 2018;77:488–94. Emery P, et al. Rheumatology 2017;56:2093–2101. No conflict of interest.